NCT06757777Not yet recruiting
Evaluation of Remnant Cholesterol Levels and Monocyte-to-HDL-cholesterol Ratio as Predictors of Coronary Artery Disease Severity in Patients With Acute Coronary Syndrome
Source: ClinicalTrials.gov · Last updated 11 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
1. Evaluation of serum level of remnant cholesterol and monocyte/HDL ratio as predictors of severity of coronary artery disease in patients with acute coronary syndrome. 2. Evaluate predictive value of remnant cholesterol serum level and monocyte/HDL ratio to detect in-hospital worse clinical outcomes and 45 days major adverse cardiac events (MACE) after acute coronary syndrome.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 54 (estimated)
- First submitted
- 26 Dec 2024
- Start date
- 8 Feb 2025
- Primary completion date
- 8 Feb 2026
- Lead sponsor
- Assiut University
- Diseases
- Coronary artery disease
- NCT number
- NCT06757777
What you commit to
- Study type: Observational
- Planned participants: 54
- From 8 Feb 2025 to the primary completion date, 8 Feb 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients on previous statin therapy.
Lab values
- Patients with severe renal dysfunction (creatinine clearance \<30 mL/min) or other contraindications to PCI.
Other
- Patients with missed data or who couldn't be followed up
Who the study is looking for
- Patients with acute coronary syndrome presented to ER of Assiut university hospital scheduled for primary PCI and able to provide informed consent.
Age in the registry: 18 years to 65 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.